FDA Expands TearCare Label to Improve Meibomian Gland Function, a First for Dry Eye
SGHT has more than doubled off its 52-week low of $3.19.
Summary
The FDA updated TearCare's indication to include improvement of meibomian gland function in evaporative dry eye disease, making it the first and only MGD treatment with this claim. This label expansion differentiates TearCare from competitors and directly addresses the underlying cause of dry eye, potentially expanding its addressable market. The update also incorporates optional debridement, broadening the system's clinical utility. This follows the company's strong Q2 results and recent OMNI Ultra clearance, reinforcing its regulatory momentum. The new indication could accelerate adoption among eye care providers seeking clinically meaningful endpoints.
At the time of this announcement, SGHT was trading at $8.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $452.8M. The 52-week trading range was $3.19 to $9.24. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.